Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Affimed N.V. AFMD
$0.86
-$0.05 (-5.83%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
137675631.00000000
-
week52high
3.53
-
week52low
0.55
-
Revenue
41353000
-
P/E TTM
-4
-
Beta
2.51211000
-
EPS
-0.64000000
-
Last Dividend
0.00000000
-
Next Earnings Date
30 мая 2023 г. в 10:59
Описание компании
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 23 июн 2022 г. |
| Piper Sandler | Overweight | 31 мар 2022 г. | |
| Cantor Fitzgerald | Overweight | 23 февр 2022 г. | |
| Truist Securities | Buy | 21 окт 2021 г. | |
| SVB Leerink | Outperform | Outperform | 12 окт 2021 г. |
| Stifel | Hold | Buy | 10 окт 2022 г. |
| Wells Fargo | Overweight | Overweight | 12 дек 2022 г. |
| SVB Leerink | Outperform | Outperform | 12 дек 2022 г. |
| Piper Sandler | Overweight | Overweight | 12 дек 2022 г. |
| HC Wainwright & Co. | Buy | 12 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
23 мар 2023 г. в 09:08
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022.
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
GlobeNewsWire
16 мар 2023 г. в 06:30
HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET.
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
GlobeNewsWire
22 февр 2023 г. в 06:30
HEIDELBERG, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Conference on Tuesday, February 28, 2023, at 8:30 a.m. EST / 14:30 CET.
Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
GlobeNewsWire
08 февр 2023 г. в 06:30
HEIDELBERG, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will present at the SVB Securities 2023 Global Biopharma Conference on Tuesday, February 14, 2023 at 2:20 p.m. EST / 20:20 CET.
7 Cheap But Risky Biotech Stocks
Barrons
18 янв 2023 г. в 13:58
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.